Is Hospital Exemption an Alternative or a Bridge to European Medicines Agency for Developing Academic Chimeric Antigen Receptor T-Cell in Europe? Our Experience with ARI-0001-Reference-Cited by-同舟云学术

Is Hospital Exemption an Alternative or a Bridge to European Medicines Agency for Developing Academic Chimeric Antigen Receptor T-Cell in Europe? Our Experience with ARI-0001

Published:2021-10-01 Issue:19-20 Volume:32 Page:1004-1007
ISSN:1043-0342
Container-title:Human Gene Therapy
language:en
Short-container-title:Human Gene Therapy

Author:

Juan Manel¹²³⁴⁵^ORCID,Delgado Julio³⁴⁵⁶,Calvo Gonzalo²³⁴⁷,Trias Esteve²⁴,Urbano-Ispizua Álvaro³⁴⁵⁶

Affiliation:

1. Inmunology Service.

2. Advanced Therapies Unit.

3. Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS).

4. Hospital Clínic de Barcelona.

5. Universitat de Barcelona.

6. Hematology Service.

7. Clinic Pharmacology, Barcelona, Spain.

Publisher

Mary Ann Liebert Inc

Subject

Genetics,Molecular Biology,Molecular Medicine

Link

https://www.liebertpub.com/doi/pdf/10.1089/hum.2021.168

Reference7 articles.

1. CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+ Relapsed/Refractory Malignancies

2. An assessment of the hospital exemption landscape across European Member States: regulatory frameworks, use and impact

3. Publication rates and reported results in a cohort of gene- and cell-based therapy trials

4. Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions

5. Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ACT To Sustain: Adoptive Cell Therapy To Sustain Access to Non-Commercialized Genetically Modified Cell Therapies;Transplantation and Cellular Therapy;2024-08

2. Current challenges in cell and gene therapy: a joint view from the European Committee of the International Society for Cell & Gene Therapy (ISCT) and the European Society for Blood and Marrow Transplantation (EBMT);Cytotherapy;2024-07

3. Enhancing pediatric access to cell and gene therapies;Nature Medicine;2024-06-17

4. Celebrating the registration of 9.000 patients treated with CAR T cells in the EBMT registry: Collection of real-world data in the context of hematopoietic cellular therapies;Best Practice & Research Clinical Haematology;2024-06

5. Polish regulatory system regarding ATMP hospital exemptions;Frontiers in Immunology;2024-05-13